Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy

A 12-year cohort study

Gregory M Lucas, Joseph A. Eustace, Stephen M Sozio, Evelyn K. Mentari, Kofi A. Appiah, Richard D Moore

Research output: Contribution to journalArticle

Abstract

Objective: To assess temporal changes in the incidence of human immunodeficiency virus-1-associated nephropathy (HIVAN), and the association with use of highly active antiretroviral therapy (HAART). Methods: HIVAN incidence and risk factors were assessed in 3976 HIV-1-infected individuals followed in clinical cohort in Baltimore, Maryland, USA from 1989 to 2001. The incidence of HIVAN, defined by biopsy or a conservative uniformly applied clinical coding protocol, was expressed in terms of person-years, and Poisson regression was used for multivariate analysis. Results: Ninety-four patients developed HIVAN over the course of the study for an incidence of 8.0 per 1000 person-years [95% confidence interval (CI), 6.5 to 9.8]. African American race and advanced immunosuppression were strongly associated with HIVAN risk. HIVAN incidence declined significantly in 1998-2001 compared with 1995-1997. Among patients with a prior diagnosis of AIDS, HIVAN incidence was 26.4, 14.4, and 6. 8 per 1000 person-years in patients not receiving antiretroviral therapy, treated with nucleoside analogue therapy only, or treated with HAART, respectively (P <0.001 for trend). In multivariate analysis, HIVAN risk was reduced 60% (95% CI, -30 to -80%) by use of HAART, and no patient developed HIVAN when HAART had been initiated prior to the development of AIDS. Conclusion: HAART was associated with a substantial reduction in HIVAN incidence. Additional follow-up will be needed to determine if renal damage in susceptible individuals is halted or merely slowed by HAART, particularly when control of viremia is incomplete or intermittent.

Original languageEnglish (US)
Pages (from-to)541-546
Number of pages6
JournalAIDS
Volume18
Issue number3
DOIs
StatePublished - Feb 20 2004

Fingerprint

AIDS-Associated Nephropathy
compound A 12
Highly Active Antiretroviral Therapy
HIV-1
Cohort Studies
Incidence
Acquired Immunodeficiency Syndrome
Multivariate Analysis
Confidence Intervals
Baltimore
Viremia
Clinical Protocols
Nucleosides
Clinical Coding
African Americans
Immunosuppression

Keywords

  • Highly active antiretroviral therapy
  • HIV-1
  • HIV-1-associated nephropathy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy : A 12-year cohort study. / Lucas, Gregory M; Eustace, Joseph A.; Sozio, Stephen M; Mentari, Evelyn K.; Appiah, Kofi A.; Moore, Richard D.

In: AIDS, Vol. 18, No. 3, 20.02.2004, p. 541-546.

Research output: Contribution to journalArticle

@article{31b9d5ba1ee2408c9be4b1cd8318e805,
title = "Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: A 12-year cohort study",
abstract = "Objective: To assess temporal changes in the incidence of human immunodeficiency virus-1-associated nephropathy (HIVAN), and the association with use of highly active antiretroviral therapy (HAART). Methods: HIVAN incidence and risk factors were assessed in 3976 HIV-1-infected individuals followed in clinical cohort in Baltimore, Maryland, USA from 1989 to 2001. The incidence of HIVAN, defined by biopsy or a conservative uniformly applied clinical coding protocol, was expressed in terms of person-years, and Poisson regression was used for multivariate analysis. Results: Ninety-four patients developed HIVAN over the course of the study for an incidence of 8.0 per 1000 person-years [95{\%} confidence interval (CI), 6.5 to 9.8]. African American race and advanced immunosuppression were strongly associated with HIVAN risk. HIVAN incidence declined significantly in 1998-2001 compared with 1995-1997. Among patients with a prior diagnosis of AIDS, HIVAN incidence was 26.4, 14.4, and 6. 8 per 1000 person-years in patients not receiving antiretroviral therapy, treated with nucleoside analogue therapy only, or treated with HAART, respectively (P <0.001 for trend). In multivariate analysis, HIVAN risk was reduced 60{\%} (95{\%} CI, -30 to -80{\%}) by use of HAART, and no patient developed HIVAN when HAART had been initiated prior to the development of AIDS. Conclusion: HAART was associated with a substantial reduction in HIVAN incidence. Additional follow-up will be needed to determine if renal damage in susceptible individuals is halted or merely slowed by HAART, particularly when control of viremia is incomplete or intermittent.",
keywords = "Highly active antiretroviral therapy, HIV-1, HIV-1-associated nephropathy",
author = "Lucas, {Gregory M} and Eustace, {Joseph A.} and Sozio, {Stephen M} and Mentari, {Evelyn K.} and Appiah, {Kofi A.} and Moore, {Richard D}",
year = "2004",
month = "2",
day = "20",
doi = "10.1097/00002030-200402200-00022",
language = "English (US)",
volume = "18",
pages = "541--546",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy

T2 - A 12-year cohort study

AU - Lucas, Gregory M

AU - Eustace, Joseph A.

AU - Sozio, Stephen M

AU - Mentari, Evelyn K.

AU - Appiah, Kofi A.

AU - Moore, Richard D

PY - 2004/2/20

Y1 - 2004/2/20

N2 - Objective: To assess temporal changes in the incidence of human immunodeficiency virus-1-associated nephropathy (HIVAN), and the association with use of highly active antiretroviral therapy (HAART). Methods: HIVAN incidence and risk factors were assessed in 3976 HIV-1-infected individuals followed in clinical cohort in Baltimore, Maryland, USA from 1989 to 2001. The incidence of HIVAN, defined by biopsy or a conservative uniformly applied clinical coding protocol, was expressed in terms of person-years, and Poisson regression was used for multivariate analysis. Results: Ninety-four patients developed HIVAN over the course of the study for an incidence of 8.0 per 1000 person-years [95% confidence interval (CI), 6.5 to 9.8]. African American race and advanced immunosuppression were strongly associated with HIVAN risk. HIVAN incidence declined significantly in 1998-2001 compared with 1995-1997. Among patients with a prior diagnosis of AIDS, HIVAN incidence was 26.4, 14.4, and 6. 8 per 1000 person-years in patients not receiving antiretroviral therapy, treated with nucleoside analogue therapy only, or treated with HAART, respectively (P <0.001 for trend). In multivariate analysis, HIVAN risk was reduced 60% (95% CI, -30 to -80%) by use of HAART, and no patient developed HIVAN when HAART had been initiated prior to the development of AIDS. Conclusion: HAART was associated with a substantial reduction in HIVAN incidence. Additional follow-up will be needed to determine if renal damage in susceptible individuals is halted or merely slowed by HAART, particularly when control of viremia is incomplete or intermittent.

AB - Objective: To assess temporal changes in the incidence of human immunodeficiency virus-1-associated nephropathy (HIVAN), and the association with use of highly active antiretroviral therapy (HAART). Methods: HIVAN incidence and risk factors were assessed in 3976 HIV-1-infected individuals followed in clinical cohort in Baltimore, Maryland, USA from 1989 to 2001. The incidence of HIVAN, defined by biopsy or a conservative uniformly applied clinical coding protocol, was expressed in terms of person-years, and Poisson regression was used for multivariate analysis. Results: Ninety-four patients developed HIVAN over the course of the study for an incidence of 8.0 per 1000 person-years [95% confidence interval (CI), 6.5 to 9.8]. African American race and advanced immunosuppression were strongly associated with HIVAN risk. HIVAN incidence declined significantly in 1998-2001 compared with 1995-1997. Among patients with a prior diagnosis of AIDS, HIVAN incidence was 26.4, 14.4, and 6. 8 per 1000 person-years in patients not receiving antiretroviral therapy, treated with nucleoside analogue therapy only, or treated with HAART, respectively (P <0.001 for trend). In multivariate analysis, HIVAN risk was reduced 60% (95% CI, -30 to -80%) by use of HAART, and no patient developed HIVAN when HAART had been initiated prior to the development of AIDS. Conclusion: HAART was associated with a substantial reduction in HIVAN incidence. Additional follow-up will be needed to determine if renal damage in susceptible individuals is halted or merely slowed by HAART, particularly when control of viremia is incomplete or intermittent.

KW - Highly active antiretroviral therapy

KW - HIV-1

KW - HIV-1-associated nephropathy

UR - http://www.scopus.com/inward/record.url?scp=1642401131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642401131&partnerID=8YFLogxK

U2 - 10.1097/00002030-200402200-00022

DO - 10.1097/00002030-200402200-00022

M3 - Article

VL - 18

SP - 541

EP - 546

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 3

ER -